Recently proposed echocardiographic cutoffs for grading right ventricular dysfunction carry prognostic value in patients with significant secondary tricuspid regurgitation but separate risk inconsistently between adjacent grades, while a stepwise combination of 2 measures may identify subclinical dysfunction that a single parameter misses, according to a new observational study. 

Transcatheter mitral valve replacement (TMVR) in a failed surgical bioprosthesis is associated with lower rates of left ventricular outflow tract obstruction, reintervention and acute kidney injury than TMVR in a failed annuloplasty ring, while early mortality and other major complications do not differ significantly, according to a new pooled analysis. 

The 2026 ACC and AHA cardiovascular care guidelines for noncardiac surgery replace the 2024 version with unchanged recommendations. The guidelines’ recommendations cover selective cardiac testing, perioperative medication management and postoperative surveillance. 

Paclitaxel-coated devices increase the risk of early major amputation in patients with chronic limb-threatening ischemia (CLTI) and tissue loss compared with uncoated endovascular devices, a substudy of the SWEDEPAD-1 trial shows. 

Before developing cardiovascular disease (CVD), patients show decline in functional aging markers, such as higher frailty levels and poorer physical functioning, data from a nested case-control study show. 

In a sub-analysis of the CENTURY trial, researchers show women with coronary artery disease (CAD) have higher coronary blood flow (CBF) versus men with CAD despite similar lifestyles and underlying medical conditions. 

The U.S. Food and Drug Administration (FDA) approved the SELUTION SLR™ Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR). 

Transcatheter aortic valve replacement (TAVR) with a self-expanding intra-annular transcatheter heart valve in patients with severe aortic stenosis (AS) at high-risk for surgery has clinical outcomes comparable with the currently available valves, a 5-year analysis of the PORTICO IDE trial shows. 

Shrinking the definition of first medical contact (FMC) in patients with acute coronary syndromes (ACS) may be doing more harm than good, researchers argue, and national cardiovascular registries may lack the data necessary to provide real-world applications in corresponding clinical trials.